abbvie-gp1656
Phase 2
AbbVieabbvie-gp1656 is one of 20 therapeutic programs targeting Hemophilia B. It is currently in Phase 2.
1
Indications
0
Total Trials
0
Active Trials
19
Competitors
Pipeline
Status by Indication[1]
Indication
Competition
Competitive Landscape
42 competitors in Hemophilia B
#DrugCompanyPhaseTrials
1Recombinant Factor IX Coagulation
PfizerApproved
IB1001
MMedexus Pharma, Inc.
Phase 3
Translarna
PPTC Therapeutics
Phase 2
BENEFIX
PfizerPhase 3
Recombinant Factor IX
BBaxalta now part of Shire
Phase 3
Rfix
PfizerPhase 3
Factor Ix
CSL BehringPhase 3
Rix-FP
CSL BehringPhase 3
Nonacog Alfa
PfizerPhase 3
Rfixfc
BBioverativ Therapeutics Inc.
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Sources
References
- [1]Open Targets Platform — Drug–disease associations for abbvie-gp1656. EMBL-EBI & Wellcome Sanger Institute.
- [2]
Details
Drug Info
Quick Facts
- Highest Phase
- Phase 2
- Company